Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

The Availability Heuristic

The Availability Heuristic

A heuristic is a general problem-solving framework (Tversky & Kahneman, 1974). You can think of these as mental shortcuts that are used to solve problems. Different types of heuristics are used in different types of situations, and the impulse to use a heuristic occurs when one of five conditions is met (Pratkanis, 1989):

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Preliminary pharmacokinetic investigation of two discoidin domain receptor 2 inhibitors in murine plasma and brain using liquid chromatography-tandem mass spectrometry analysis.

Scientific reports·2026

Same author

External Evaluation of Population Pharmacokinetic Models of Cabotegravir, During Its Oral and Intramuscular Administration in HIV-Infected Patients.

CPT: pharmacometrics & systems pharmacology·2026

Same author

Evaluation of dasatinib and ponatinib for the control of CD123 CAR-T cell functionalities.

Molecular therapy. Oncology·2026

Same author

Beneficial effect of resveratrol on T cell oxidative metabolism and anti-tumor function is conditioned by prior <i>in vivo</i> T cell history.

Molecular therapy. Methods & clinical development·2025

Same author

Trifluridine- and tipiracil-induced DPD inhibition mimicking DPD deficiency: a case report.

Frontiers in oncology·2025

Same author

Therapeutic Drug Monitoring of Long-Acting Cabotegravir and Rilpivirine in a National Cohort of People With HIV-1: First Results From the ANRS-MIE CARLAPOP Study.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2025

Same journal

Pharmacology of pruritus (pathophysiology, therapeutic targets).

Therapie·2026

Same journal

Barriers to prescribing methylphenidate for adults with ADHD: A qualitative study.

Therapie·2026

Same journal

[Self-medication and its factors amongst Navymen aboard surface ships of the French Navy at sea: A descriptive study].

Therapie·2026

Same journal

Subacute cutaneous lupus erythematosus induced by ticagrelor: Recurrence after rechallenge.

Therapie·2026

Same journal

Multiple HIV virological failures related to bictegravir-valproic acid interaction evidenced by therapeutic drug monitoring: A retrospective study.

Therapie·2026

Same journal

Indication-related misuse of oral fluoroquinolones in adults by general practitioners in France.

Therapie·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Mar 18, 2026

High-throughput Fluorometric Measurement of Potential Soil Extracellular Enzyme Activities

High-throughput Fluorometric Measurement of Potential Soil Extracellular Enzyme Activities

Published on: November 15, 2013

[Not Available].

Stéphane Bouchet¹, Bernard Royer², Chantal Le Guellec³

¹CHU Pellegrin, Université de Bordeaux, France.

|July 10, 2016

Summary

This summary is machine-generated.

Therapeutic Drug Monitoring (TDM) for imatinib in chronic myelogenous leukemia (CML) is becoming increasingly important. Studies show a link between imatinib trough concentrations and treatment effectiveness, suggesting TDM could optimize CML therapy.

Keywords:

imatinib inhibiteur de tyrosine-kinase level of evidence niveau de prevue pharmacokinetic/pharmacodynamic relationship relation pharmacocinétique/pharmacodynamie suivi thérapeutique pharmacologique therapeutic drug monitoring tyrosine-kinase inhibitor

More Related Videos

Ex Vivo Assessment of Contractility, Fatigability and Alternans in Isolated Skeletal Muscles

Ex Vivo Assessment of Contractility, Fatigability and Alternans in Isolated Skeletal Muscles

Published on: November 1, 2012

A Submerged Filter Paper Sandwich for Long-term Ex Ovo Time-lapse Imaging of Early Chick Embryos

A Submerged Filter Paper Sandwich for Long-term Ex Ovo Time-lapse Imaging of Early Chick Embryos

Published on: December 28, 2016

Related Experiment Videos

Last Updated: Mar 18, 2026

High-throughput Fluorometric Measurement of Potential Soil Extracellular Enzyme Activities

High-throughput Fluorometric Measurement of Potential Soil Extracellular Enzyme Activities

Published on: November 15, 2013

Ex Vivo Assessment of Contractility, Fatigability and Alternans in Isolated Skeletal Muscles

Ex Vivo Assessment of Contractility, Fatigability and Alternans in Isolated Skeletal Muscles

Published on: November 1, 2012

A Submerged Filter Paper Sandwich for Long-term Ex Ovo Time-lapse Imaging of Early Chick Embryos

A Submerged Filter Paper Sandwich for Long-term Ex Ovo Time-lapse Imaging of Early Chick Embryos

Published on: December 28, 2016

Area of Science:

Pharmacology
Oncology
Clinical Chemistry

Context:

Imatinib was the gold standard for chronic myelogenous leukemia (CML) treatment.
Therapeutic Drug Monitoring (TDM) was rarely used in oncology.
Interindividual variability in imatinib response was observed, linked to CYP3A4 metabolism.

Purpose:

To investigate the pharmacokinetic/pharmacodynamic relationship of imatinib.
To determine the necessity and utility of TDM in CML management.
To establish an effectiveness threshold for imatinib trough concentrations.

Summary:

Recent studies confirm significant interindividual variability in imatinib response.
A correlation exists between imatinib trough concentrations and clinical outcomes, with a threshold near 1000 ng/mL linked to better responses.
TDM may aid in assessing adherence, lack of response, and drug interactions, though further studies are needed.

Impact:

TDM for imatinib in CML shows potential utility, moving from 'recommended' to 'potentially useful' evidence levels.
Optimizing imatinib dosage through TDM could improve patient outcomes in CML.
This research highlights the evolving role of TDM in personalized cancer therapy.